PT-141 10mg 10mL Vial
PT-141, also known as Bremelanotide, is a peptide being studied for its potential to support sexual health by acting on the nervous system pathways involved in arousal and desire. It offers a natural approach that may help improve libido and sexual response.
- May help enhance sexual desire and arousal
- May support erectile function
- May increase overall sexual satisfaction
- May contribute to hormone balance and support
- Dose: 1-2mg
- 1-2mg dosing 1-2hours before engaging in intimacy
- Draw up 40 units (0.4mL) per dose
- *First time trial, test 1mg (20 units (0.2mL) subq, wait 30 minutes to determine any blood pressure or GI effects and if no effects, proceed with additional 1mg (20 units (0.2mL) subq dose.
- Duration: As needed
- Reconstitute: add 2mL bacteriostatic water to the 10mg vial of PT-141
- Duration of effects after administration can last 24-72 hours.
- Not recommended to use more than 2 injections, (not for use with PDE5 Inhibitor, discontinue use if tachycardia develops, monitor closely if hypertensive).
- Add L-theanine capsule 30 minutes prior to help if experiencing nausea
- Subcutaneous injection
- Melanocortin Receptor Activation:
- PT-141 is a selective melanocortin receptor agonist that primarily targets melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors located within the central nervous system. Activation of these receptors modulates neuroendocrine circuits involved in sexual desire and arousal.
- Central Nervous System Pathways:
- Unlike phosphodiesterase inhibitors that act via peripheral vasodilation, PT-141 operates centrally by influencing hypothalamic pathways responsible for sexual motivation and behavior. This mechanism directly enhances sexual drive independent of vascular function.
- Dopaminergic and Oxytocinergic Modulation:
- Stimulation of MC4R receptors enhances dopaminergic neurotransmission and promotes the release of oxytocin—both critical mediators of sexual arousal, bonding, and reward. This neurochemical modulation amplifies sexual desire and positive affective responses.
- Autonomic and Neuroendocrine Regulation:
- PT-141 influences sympathetic nervous system output and integrates neuroendocrine signals that coordinate arousal responses. These effects result in heightened sexual readiness and improved central activation of arousal networks.
- Distinct Mechanistic Profile:
- Through its central melanocortin-mediated mechanism, PT-141 provides a unique therapeutic pathway for addressing hypoactive sexual desire and arousal disorders. Its independence from nitric oxide–mediated vasodilation makes it effective in both male and female patients, including those unresponsive to PDE5 inhibitors.
- Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.